Introduction
Peritoneal infection in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) is the most common cause of morbidity and treatment failure. While the incidence of infection has fallen over the last decade, bacterial infection remains the most common cause of these infective episodes. The vast majority, about 75%, are caused by Gram-positive bacteria, mainly Staphylococcus spp., while about 20% are caused by Gram-negative bacilli. 1 Quinolones, in particular ciprofloxacin, have been used in monotherapy and in combination treatments. They have the advantage of oral administration and good penetration into the peritoneal dialysis fluid (PDF), but are limited by poor activity against many Gram-positive species. 2 Ofloxacin has a similar antibacterial spectrum to ciprofloxacin against Gram-positive bacteria and is, on average, one doubling dilution less active against Gram-negative bacilli. 3 In patients with normal renal function, in contrast to ciprofloxacin, ofloxacin is only slightly metabolized and excreted virtually unchanged via the kidneys. 4 During renal failure the half-life of ofloxacin is prolonged (up to 50 h) and drug accumulation may occur. 5, 6 The main metabolites of ofloxacin, desmethyl ofloxacin and ofloxacin-Noxide, may accumulate during renal failure and dose reduction in renal impairment is recommended. 7 The aim of the study was to investigate the pharmacokinetics of ofloxacin and its two main metabolites in CAPD patients with peritonitis by administering ofloxacin 400 mg/day for 7 days. This dose was unmodified for renal impairment and was designed to result in drug accumulation such that therapeutic serum and PDF concentrations were maintained for several days after cessation of therapy.
Materials and methods

Ofloxacin treatment
Seven patients (two females, five males; mean age 67.6 years (range 45-76 years)) with end-stage renal disease (mean serum creatinine 639.1 mol/L (range 376-830 mol/L) and CAPD-related peritonitis, received oral ofloxacin (400 mg/od) for 7 days. Pre-dose and 2 h postdose serum samples were collected during the 7 day treatment period and single random samples were collected on the 5 days after the end of therapy. Each patient received four 2 L exchanges of PDF per day and this was collected throughout the 12 day study period. The study was approved by the Local Research Ethics Committee at Southmead Hospital. 
Assay
Ofloxacin, desmethyl-ofloxacin and ofloxacin-N-oxide were determined in serum and PDF by HPLC using a modified method of White. 6 The inter-assay and intra-assay reproducibility was 5% for the ofloxacin standard and 10% for the metabolite standards. The accuracy of the assay (measured concentration target concentration/ target concentration 100) was 5% for the ofloxacin and metabolite controls.
Pharmacokinetic methods
The serum half-lives (t 1/2 ) were calculated from log-linear plots of concentration against time using a best fit line fitted by eye. The mean steady state ofloxacin concentration (C ss ), plasma clearance (Cl p ) and volume of distribution (V D ) were calculated by a software package (Prizm, GraphPad Software Inc., San Diego, CA, USA) using a single compartment hyperbola to fit to the data. The bioavailability was assumed to be 95%. 4 
Results
The mean S.D. (n 7) pre-dose and 2 h post-dose serum ofloxacin concentrations are plotted against day of study in Figure 1 . Ofloxacin accumulated in serum over the 7 days of dosing with the mean pre-dose concentration increasing from 3.0 1.3 mg/L on day 2 to 6.7 mg/L 2.9 on day 7. Similarly, the mean serum post-dose ofloxacin concentrations increased from 3.9 2.0 mg/L on day 1 to 10. Figure 2 . Mean ofloxacin PDF concentrations increased from 2.5 1.3 mg/L on day 1 to 6.1 2.0 mg/L on day 7 and were equivalent to serum ofloxacin concentrations. Serum half-lives were calculated for ofloxacin using the serum concentrations from day 7 to day 12. The half-life was prolonged, 32 7 h (range 23-42 h) and a mean ofloxacin concentration of 1.0 0.8 mg/L was measured on the final day of the study (5 days after completion of therapy). The plasma clearance was 1.33 L/h 0.42. The mean desmethyl ofloxacin and ofloxacin-Noxide serum concentrations are plotted in Figure 1 . Both metabolites accumulated over the course of therapy, increasing to a maximum mean serum concentration of 0.7 0.2 mg/L between days 6 and 8 for desmethyl ofloxacin and 1.2 0.5 mg/L on day 8 for ofloxacin-N-oxide. Only very low desmethyl ofloxacin concentrations were measured on day 1 of the study and ofloxacin-N-oxide was not detected until 24 h after the start of therapy. PDF concentrations of desmethyl ofloxacin and ofloxacin-Noxide were similar to those in the sera and increased up to day 8, declining thereafter. In both serum and PDF the concentration of ofloxacin-N-oxide was greater than that of desmethyl ofloxacin. The serum half-lives of both desmethyl ofloxacin and ofloxacin-N-oxide were greater than that of ofloxacin (desmethyl ofloxacin t 1/2 45 26 h (n 4); ofloxacin-N-oxide t 1/2 44 15 h (n 5)). The percentage recovery of ofloxacin in the PDF was low (12. 5 6.1%) and even when the metabolites were added in, only 15.5 8.1% of the total dose could be accounted for by recovery from the PDF.
Discussion
CAPD has become one of the main forms of treatment for patients with end-stage renal disease. Peritonitis often does The pharmacokinetics of oral ofloxacin not require hospitalization and patients can self-administer antibiotics in the community. 8 Hence oral therapy for CAPD peritonitis is a worthwhile goal.
Ofloxacin accumulated in serum and PDF of patients over the 7 days of treatment. Mean trough serum concentration of 4 mg/L were maintained between days 3 and 9 of the study and a mean trough level of 1.0 mg/L was measured on the final day of study. Such concentrations are sufficient to treat most Enterobacteriaceae and many Gram-positive bacteria. 3 In the PDF ofloxacin concentrations were for the most part 2 mg/L between days 1 and 9.
Furthermore, the metabolites may well add to the antimicrobial activity of the parent compound. Although ofloxacin-N-oxide has been previously demonstrated to have little antimicrobial activity, 6, 9 desmethyl ofloxacin has almost equal activity to ofloxacin against Enterobacteriaceae, Haemophilus influenzae, Neisseria meningitidis and Pseudomonas aeruginosa but is half as active as the parent against Gram-positive bacteria. 9 It is highly likely that desmethyl ofloxacin at the concentration achieved in this study will contribute to the overall activity of the parent drug.
In summary, a 7 day 400 mg once-daily ofloxacin regimen offers PDF and serum concentrations which are likely to be effective in treating CAPD peritonitis for a period of 12 days. In addition, once-daily oral administration has the advantage of improving patient compliance and timing of the dose to avoid interaction with aluminium salts.
